Cogent Biosciences Inc expected to post a loss of 54 cents a share - Earnings Preview

Cogent Biosciences

04/08/2023 16:37

* Cogent Biosciences Inc  COGT.OQ   COGT.O  is expected
to show no
change in quarterly revenue when it reports  results on August 7
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Cogent Biosciences
Inc is
for a loss of 54 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cogent
Biosciences Inc is $22​, above​ its last closing price
of $12.10. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.58       -0.57      -0.54     Beat    5.4
 Dec. 31 2023  -0.54       -0.52      -0.56     Missed  -8.3
 Sep. 30 2022  -0.53       -0.51      -0.50     Beat    2.6​
 Jun. 30 2022  -0.68       -0.65      -0.71     Missed  -9
 ​​Mar.        -0.55       -0.52      -0.68     Missed  -29.5
 31 2022                                                
 Dec. 31 2021              -0.46      -0.60     Missed  -30.4​
 Sep. 30 2021  -0.42       -0.41      -0.48     Missed  -18.3
 Jun. 30 2021  -0.40       -0.36      -0.43     Missed  -20.6
 This summary was machine generated August 4 at 15:37 GMT.  All
figures in US dollars  unless otherwise stated